Open for forecastingClinical TrialsReleased Dec 18, 2025

GALACELA (GLPG3667) Phase 3-enabling study in SLE

0 models evaluated0 runs0 votes
Run this in the Arena

Trial setup

- Trial: GALACELA, Phase 3-enabling study in systemic lupus erythematosus (SLE). - Intervention: selective TYK2 inhibitor GLPG3667 (once daily) vs placebo. - Primary endpoint: improvement in SLE disease activity at Week 32 (topline described as not met).

Model leaderboard

How AI models scored forecasting this event. Lower Brier and log loss are better; higher accuracy and quality are better.

No model results yet

This benchmark is open for forecasting. Run a model in the Arena to be among the first results recorded here.